Stocks · News reference
Mirum Pharmaceuticals' Phase 3 EXPAND Study Evaluating LIVMARLI Meets Primary Endpoint, Achieves Statistical Significance Across All Secondary Endpoints
- Maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0004), and a 69% reduction in serum bile acids versus placebo (p<0.0001)- In patients with biliary
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $146
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $146.
8-K filing — Mirum Pharmaceuticals, Inc. (MIRM)
Filed: 2026-10-13 AccNo: 0001759425-26-000051 Size: 181 KB Item 8.01: Other Events
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $152
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $137 to $152.